Compare CVS Health Corp (CVS) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Micron Technology, Inc. — how do they compare? CVS Health Corp trades at $93.65 (market cap $122.36B), while Micron Technology, Inc. trades at $880.53 (market cap $972.41B). The key difference: Micron Technology, Inc. is far larger — about 7.9× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | MU | |
|---|---|---|
Market Cap | $122.36B | $972.41B |
Sector | Health | Technology |
52-Week High | $110.60 | $1.21K |
52-Week Low | $65.51 | $115.79 |
Enterprise Value | $184.71B | $952.76B |
Dividend Yield | 2.78% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Micron Technology (MU) trades at $877.57, down 0.44% on the day, with technical indicators showing a neutral overall signal and bullish moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $25.11 versus $20.98 expected, driven by robust AI memory demand. Revenue surged to $37.38 billion in 2025, with net income margin at 55.91%. Analyst consensus is overwhelmingly bullish with an 81.43% buy rating and a $1,540 price target.
Outlook remains positive due to structural demand for high-bandwidth memory in AI, but risks include cyclical pricing pressures and competitive capacity expansions. The stock offers growth potential amid tight supply conditions, though volatility from valuation concerns and macroeconomic factors persists. Key support sits at $848 with resistance at $906.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
